Paid Multiple Sclerosis Clinical Trials
Multiple sclerosis clinical trials now enrolling. Access new disease-modifying therapies. Compensation up to $4,500. Studies for relapsing and progressive MS.
Compensation
$2,000 - $4,500
Duration
52-104 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18-60 years
- Diagnosis of relapsing-remitting or secondary progressive MS (McDonald criteria)
- Recent disease activity (relapse or MRI activity within 1-2 years)
- EDSS score typically 0-6.5 (study dependent)
- Stable neurologic status for at least 30 days
- Willing to undergo MRI scans
Who May Not Qualify
- Primary progressive MS (unless study-specific)
- Prior treatment with certain high-efficacy therapies (study-dependent)
- Progressive multifocal leukoencephalopathy (PML) history
- Significant cardiac, hepatic, or renal disease
- Pregnancy or unwillingness to use contraception
Frequently Asked Questions
What MS treatments are being studied?
+
Studies are evaluating new disease-modifying therapies including BTK inhibitors, anti-CD20 antibodies, remyelinating agents, and neuroprotective treatments. Options exist for various MS types and treatment histories.
How often will I need MRI scans?
+
MRI is a key measure in MS studies. Expect brain (and sometimes spinal cord) MRI at screening, then typically every 3-6 months during the study.
Can I continue my current MS therapy?
+
This varies by study. Some trials allow continued background therapy, while others require a washout period. The specific requirements depend on your current medication and the study drug.
What happens if I have a relapse during the study?
+
Relapses are carefully documented and treated according to standard protocols (typically IV corticosteroids). The study team monitors for relapses and provides appropriate care.